Distinguished prognosis after hepatectomy of HBV-related hepatocellular carcinoma with or without cirrhosis: a long-term follow-up analysis
Publication in refereed journal


Times Cited
Altmetrics Information
.

Other information
AbstractBackground: Conflicting results have often been observed for the prognosis of hepatocellular carcinoma (HCC) patients, but few studies have attempted to explore the reasons for the conflicting results. We aimed to distinguish the prognosis of patients with HCC with cirrhosis (HCC-C) and that of patients with HCC without cirrhosis (HCC-NC). Methods: Patients with hepatitis B virus (HBV)-associated HCC treated by curative liver resection at a single institution between 1995 and 2013 were retrospectively evaluated. Kaplan–Meier and multivariate analyses were performed to identify risk factors, including tumor-related factors, hypoxia-inducible factor 1α expression, HBV X protein (HBx) expression, and HBx double mutations for overall survival and recurrence-free survival in these patients. Results: The long-term prognosis of HCC-NC patients is better than that of HCC-C patients. Male sex, poor differentiation, preoperative serum alanine aminotransferase level greater than 80 IU/L, and α-fetoprotein level greater than 400 ng/mL were risk factors for overall survival among HCC-NC patients but not among HCC-C patients, and age greater than 50 years was associated with poor overall survival only in cirrhotic patients. HCC-C patients benefit more from antiviral therapy following curative hepatectomy than do HCC-NC patients. The clinical value of the biomarkers hypoxia-inducible factor 1α, HBx, and HBx double mutations for predicting HCC prognosis was significantly different between these two groups. Conclusions: There were differences in tumor-related prognostic factors, effectiveness of the antiviral therapy after hepatectomy, and biomarkers between HCC-C and HCC-NC patients, indicating that subgroup analysis of the prognostic factors may result in better management of HCC and that HCC patients, especially those with liver cirrhosis, should be given antiviral therapy.
All Author(s) ListYang S.-L., Liu L.-P., Sun Y.-F., Yang X.-R., Fan J., Ren J.-W., Chen G.G., Lai P.B.S.
Journal nameJournal of Gastroenterology
Detailed description51(7):722-32. doi: 10.1007/s00535-015-1146-0. .
Year2016
Month7
Day1
Volume Number51
Issue Number7
PublisherSpringer Verlag
Place of PublicationGermany
Pages722 - 732
ISSN0944-1174
LanguagesEnglish-United Kingdom
KeywordsAntiviral therapy, Biomarkers, Cirrhosis, Hepatectomy, Hepatocellular carcinoma, Prognosis

Last updated on 2020-19-10 at 02:51